Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ovarian cancer recurrent Trials in Disease

10 / 18 trials open to patients19 countries

Clinical trials for Ovarian cancer recurrent

Recruiting trials first

See all 18 trials →
Quick filters

18 clinical trials in this condition

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Ovarian cancer recurrent

Recruiting

Evaluation of Raludotatug Deruxtecan With Carboplatin, Paclitaxel, or Bevacizumab in Relapsed High-grade Serous Ovarian, Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.
See all 18 trials →filters applied: condition = Ovarian cancer recurrent

In short

This article provides detailed information about 17 ongoing clinical trials studying new treatments for recurrent ovarian cancer. These trials are testing various medications and treatment combinations across multiple countries in Europe, offering potential treatment options for patients whose cancer has returned after initial therapy.

Summary

These 17 clinical trials represent a diverse range of investigational treatments for recurrent ovarian cancer. A significant number of trials are concentrated in countries such as France, Spain, Belgium, and Italy, reflecting strong research activity in these regions. Several trials focus on combination therapies, including immunotherapy agents like pembrolizumab and targeted therapies such as olaparib and avutometinib. Many studies specifically target platinum-resistant or platinum-sensitive disease, recognizing the different treatment needs for these patient populations. The trials also emphasize personalized medicine approaches, with some requiring specific genetic markers such as BRCA status, HLA-A2 phenotype, or folate receptor-alpha expression. Overall, these studies aim to improve treatment outcomes, extend progression-free survival, and enhance quality of life for patients with recurrent ovarian cancer.

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Related conditions in the same therapeutic area

Ovarian cancer 91Fallopian tube cancer 30Endometrial cancer 22Breast cancer 20Ovarian epithelial cancer 18Non-small cell lung cancer 16Malignant peritoneal neoplasm 12Cervix carcinoma 11Gastric cancer 9Colorectal cancer 8Transitional cell carcinoma 8Oesophageal adenocarcinoma 7Neoplasm malignant 6Ovarian cancer metastatic 6Ovarian cancer stage III 6
Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.